-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 AUbWFKRwRmDdx3ubPU1hyLPc1jODTeMsXk3i4+A1017JoMfKhDZRavqQWJvhjB4p
 avvgL+VvPCM0/w9KbK9fwQ==

<SEC-DOCUMENT>0001102624-10-000337.txt : 20100805
<SEC-HEADER>0001102624-10-000337.hdr.sgml : 20100805
<ACCEPTANCE-DATETIME>20100805101415
ACCESSION NUMBER:		0001102624-10-000337
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20100805
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100805
DATE AS OF CHANGE:		20100805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		10993034

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL CORPORATION 8-K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: August    05, 2010</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align=center colspan=2 width="40%" valign="top">
<b>DE</b><br>
(State or other jurisdiction <br>of incorporation)
</td>
<td align=center width="20%" valign="top">
<b>001-12934</b><br>
(Commission File Number)
</td>
<td align=center colspan=2 width="40%" valign="top">
<b>01-0382980</b><br>
(IRS Employer <br>Identification Number)
</td>
</tr>
<tr><td colspan=5><br></td></tr>
<tr>
<td align="center" colspan=2>
<b>56 Evergreen Drive</b><br>
(Address of principal executive offices)
</td>
<td>&nbsp;</td>
<td align="center" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
</tr>
<tr><td colspan=5 align=center><br>
<b>207-878-2770</b><br>(Registrant's telephone number, including area code)
</td></tr>
<tr><td colspan=5><br></td></tr>
<tr><td colspan=5 align=center>
<b>Not Applicable</b><br>(Former Name or Former Address, if changed since last report)<br>
</td></tr>
</table>
</center>
<br><br>
</b>
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:<br>
<dl>
 <dd><font face="wingdings">o</font> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<br>
 <dd><font face="wingdings">o</font> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  <br>
 <dd><font face="wingdings">o</font> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

  <br>
</dl>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On August 5th, 2010 ImmuCell Corporation (the "Company") issued a press release announcing financial results for the three-month and six-month periods ended June 30, 2010.  The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<br>
<br>The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<br>
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br />
<br>

<p>
<b>(a) Financial statements:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(b) Pro forma financial information:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(c) Shell company transactions:</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  None<br>
<b>(d) Exhibits</b><br>
&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated August    05, 2010</a></b>
<br>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<br>
<table border="0" width="100%">
<tr>
<td width="50%" valign=top>
Dated: August    05, 2010<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President and CEO</i><br>
</td></tr>
</table>
<hr>
<center>
<table border=0 width="100%">
<tr><td colspan=2>
<center><b>Exhibit Index</b></center>
</td>
</tr>
<tr>
<td width=50% align=center><b><u>Exhibit No.</u></b></td>
<td width=50% align=center><b><u>Description</u></b></td>
</tr>
<tr>
<td align=center>99.1</td>
<td align=center>Press Release of ImmuCell Corporation dated August    05, 2010</td>
</tr>
</table>
</center>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL CORPORATION PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Financial Results for Second Quarter of 2010 </b>
<p>PORTLAND, ME -- (Marketwire - August    05, 2010) -   <b>ImmuCell Corporation </b>(NASDAQ: ICCC) today announced the results of its operations for the three-month and six-month periods ended June 30, 2010.
</p>
<p>
For the three-month period ended June 30, 2010, product sales increased by 8%, or $77,000, to $1,078,000 in comparison to the same period in 2009. For the six-month period ended June 30, 2010, product sales decreased by 3%, or $71,000, to $2,389,000 in comparison to the same period in 2009. Year-to-date domestic sales increased by approximately 8%, but this increase was more than offset by a decline in foreign sales. As of June 30, 2009, the backlog of <b>First Defense</b>&#174; orders aggregated $287,000. There was no backlog as of June 30, 2010.
</p>
<p>
"In this economy and specifically in this dairy market with low milk prices and high feed costs, we are fortunate to see an 8% increase in our domestic product sales," commented Michael F. Brigham, President and CEO. "We believe that the level of domestic sales of <b>First Defense</b>&#174; that we are seeing, at a time when our customers are taking cost-cutting measures, indicates the value of this technology to producers."
</p>
<p>
The loss before income taxes was $(37,000) during the three-month period ended June 30, 2010 in comparison to a loss before income taxes of $(283,000) during the same period in 2009. The net loss was $(6,000), or less than $(0.01) per share, during the three-month period ended June 30, 2010 in comparison to a net loss of $(148,000), or $(0.05) per share, during the same period in 2009. The loss before income taxes was $(102,000) during the six-month period ended June 30, 2010 in comparison to a loss before income taxes of $(319,000) during the same period in 2009. The net loss was $(60,000), or $(0.02) per share, during the six-month period ended June 30, 2010 in comparison to a net loss of $(182,000), or $(0.06) per share, during the same period in 2009.
</p>
<p>
Cash, cash equivalents and short-term investments decreased by 8%, or $369,000, to $4,217,000 at June 30, 2010 as compared to $4,585,000 at December 31, 2009. Stockholders' equity decreased by less than 1%, or $45,000, to $9,577,000 at June 30, 2010 as compared to $9,622,000 at December 31, 2009. The Company had 2,971,000 shares of common stock outstanding as of June 30, 2010.
</p>
<p>
Other news/milestones:<br>
In July, we entered into a Development and Manufacturing Agreement with Lonza Sales Ltd. of Basel, Switzerland. This contract covers terms under which we will pay Lonza to exclusively i) adapt our proprietary Nisin manufacturing process at commercial scale and ii) manufacture the Nisin Active Pharmaceutical Ingredient for use in <b>Mast Out</b>&#174;, which is subject to approval by the U.S. Food and Drug Administration before any sales can be made. Financial obligations of the Company to Lonza are staged on a commitment-by-commitment basis, as the intended development process is conducted. Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries.
</p>
<p>
<pre>
                                        (Unaudited)         (Unaudited)
                                     Three Months Ended   Six Months Ended
                                          June 30,            June 30,
                                     ------------------  ------------------
(In thousands, except per share
 amounts)                              2010      2009      2010      2009
                                     --------  --------  --------  --------
Revenues:
Product Sales                        $  1,078  $  1,000  $  2,389  $  2,461
Other Revenues                              1         1         2         2
                                     --------  --------  --------  --------
Total Revenues                          1,079     1,001     2,391     2,463

Cost and expenses:
Product costs                             459       513     1,032     1,253
Product development expenses              333       489       739       921
Sales, marketing and administrative
 expenses                                 333       315       741       677
                                     --------  --------  --------  --------
Total costs and expenses                1,125     1,317     2,512     2,851
                                     --------  --------  --------  --------

Net operating loss                        (46)     (316)     (121)     (388)

Interest and other income                   9        33        19        69
                                     --------  --------  --------  --------

Loss before income taxes                  (37)     (283)     (102)     (319)
Income tax benefit                        (31)     (135)      (42)     (137)
                                     --------  --------  --------  --------
Net loss                             $     (6) $   (148) $    (60) $   (182)
                                     ========  ========  ========  ========

Net loss per common share:
Basic                                $  (0.00) $  (0.05) $  (0.02) $  (0.06)
Diluted                              $  (0.00) $  (0.05) $  (0.02) $  (0.06)
                                     ========  ========  ========  ========

Weighted average common shares
 outstanding:
Basic                                   2,971     2,971     2,971     2,947
Diluted                                 2,971     2,971     2,971     2,947


                                                 At June 30,    At December
(In thousands)                                       2010         31, 2009
                                                -------------  -------------
Cash, cash equivalents and short-term
 investments                                    $    4,217     $    4,585
Total assets                                         9,905          9,985
Net working capital                                  5,962          5,944
Stockholders' equity                            $    9,577     $    9,622
</pre>
</p>
<p>
Our purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. Press releases and other information about the Company are available at our web-site (http://www.immucell.com).

</p>
<pre>
<b>Contact:
</b>Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
